Background: For patients with an increased risk of developing myopathy with statin treatment, guidelines recommend to measure CK before and 6-12 weeks after initiating statin treatment. Further, in clinical trials of statins, the number of patients experiencing elevated creatine kinase (CK) serum activity is commonly reported as a safety parameter. Usually exceeding the upper limit of normal (ULN) is used as the basis of description to characterize muscular damage potentially caused by statins. Therefore, basic data on both, proportions of patients with specific CK increases, and absolute and relative CK increases, would be helpful to assess potential CK chances in patients. However, no such data are available so far. Methods: CK activity was measured in a group of blood donors (n=40) at two occasions 10 weeks apart. The 95 th percentile of absolute and relative CK increases was selected to separate true from irrelevant changes. A CK difference was defined to be true if a random measurement error of 10% was exceeded. The numbers of subjects with true CK differences were characterised by both measurements being under, crossing, or being above ULN, and twice ULN, respectively. Results: Five percent of subjects (95 th percentile) had an increase of CK more than 139% (men) or 120% (women), respectively, as compared with the first measurement. Five percent of subjects had an absolute difference of at least 94 U/l (men) and 16 U/l (women), respectively. Thirty-one percent of subjects had both CK activities below 2 times the ULN. Six percent of them had the first measurement under and the second above ULN. In three percent, the first measurement was under and the second above 2 times the ULN. In no subject, the first and the second measurement was above 2 times the ULN. Conclusion: It is concluded that CK serum activity substantially varies between two measurements. The present data provide the basis for developing reference ranges of CK activity pairs by simple variables that can be useful for practitioners and trialists.
INTRODUCTION
In statin therapy, efforts need to be directed to protect patients from myopathy. Patients at risk to develop myopathy should be identified at an early stage. Therefore, experts recommend to measure CK serum activity before and after initiating statin therapy in patients at risk [1] . If muscle complaints arise during treatment, CK analysis should be repeated after 6 to 12 weeks [2] . Although reference ranges for single-time CK serum activities have been established, no such data on intra-individual CK pairs are available.
We therefore aimed to characterise variation of CK pairs in healthy blood donors. These data should subsequently serve to establish reference ranges of CK pairs in patients starting statin therapy. 
MATERIALS AND METHODOLOGY

Participants
Blood donors of a university-based public blood donation center participated in this project. Inclusion criteria were age >40 years (because statins are rarely used in younger adults) and informed consent. Exclusion criteria, based on their potential to be associated with CK increase, were alcohol abuse during the previous 3 days, or history of alcoholism, asthma attack during the previous 3 days, or cough attack, seizure during the previous 3 days, massages during the previous 3 days, hypertensive crisis, intramuscular injection during the previous 7 days, known liver disease, muscle ache, myocardial infarction during the previous 6 months, percutaneous coronary intervention during the previous 6 months, blunt trauma, muscle disease (myositis, polymyositis, dermatomyositis, progressive muscular dystrophy Duchenne, congenital myopathy), surgical procedures during the previous 6 months, serious disease, malignant disease or chemotherapy, heavy physical exercise during the previous 3 days (see below), use of statins or corticosteroids. These criteria were part of the informed consent. Data on ethnic background, muscle ache, drug use, body weight and height, and massages, sports or physical activity (definition scale: 0 = no sport or physical activity, 1 = light sport or physical activity, e.g., walking, 2 = medium sport or physical activity, e.g., aerobic, jogging, 3 = heavy sport or physical activity, e.g., competitional sport, during the previous 3 days) were collected using a separate questionnaire. The ethical committee of the Medical Faculty of the University of Tübingen approved the study protocol.
Analysis
CK serum activity was measured on two occasions (CK1 and CK2), about 10 weeks apart, in each subject. All tests were performed in one laboratory, using the modified method by Szasz using the ADVIA 1650 Chemistry Systems Bayer kit. The CK assay used was the standard 37 °C IFCC (International Federation of Clinical Chemistry) method. The upper limit of normal (ULN) was 170 U/l (women) and 190 U/l (men), respectively.
A random error of 10% was assumed, based on the CK measurement method's coefficient of variation (CV) of 3% and a resulting confidence range (= 3 CV) of about 10%.
Target variables: The following target variables were described: -95th percentile of the absolute differences (CK2-CK1) and -95th percentile of the relative differences ((CK2/CK1) x 100%).
Values exceeding these limits were considered abnormal. No parametric distribution was assumed for CK. 90% confidence intervals (CI) were calculated using the percentile method with bootstrap samplings (n=1000, a commonly used sample size) [3] . Additional target variables were defined using the following limits ( Table 3) : upper limit of normal (ULN), 1.1-fold of first value (taking 3 CV into account), and twice ULN (based on arbitrary limits found in published reports, e.g. [4, 5] ).
Nonparametric 90% confidence intervals were determined for proportions of subjects meeting these criteria. Bootstrap sampling and data analyses were performed with the SAS software version 9.1. Tests for confounding (age, sex, body mass index, physical activity) were performed using Wilcoxon rank sum tests for unpaired samples and Chi square tests, respectively. All tests were done in an exploratory fashion. The significance level was set to 5%.
RESULTS
40 blood donors met the inclusion criteria. Four male donors reporting heavy sport or muscle ache were excluded. All 36 donors were of Caucasian ethnic background. Seven participants reported using drugs, i.e. four women (1 contraceptive, 2 angiotensin-converting enzyme inhibitor, 1 thyroxin) and three men (thyroxin, beta blocker, angiotensin receptor blocker), see Table 1 .
CK serum activity pairs and the target variables are shown in Table 2 . Differences greater than 94 U/l (men) or 16 U/l (women), respectively, and deviations of CK2 in relation to CK1 of more than 139% (men) or 120% (women) were found to occur in 5% of subjects.
Fig. (1) shows the distribution of the individual CK activity difference values (CK2-CK1
). An outlier is observed among the male group. Table 3 shows the absolute and relative frequencies of subjects whose CK values met the logical operations (random error of 10%, once or twice ULN). 25% of donors had significant variations within the reference range, and 11% of subjects had such variations above ULN. Testing for potential confounders (age, sex, body mass index, physical activity), sex gives a borderline significant association (p=0.05): Only 3 out of 15 subjects meeting at least 1 variation criterion were women.
DISCUSSION
Using pre-specified criteria, the present data show that individual pairs of CK serum activities are variable. On the basis of these variation criteria and results it seems appropriate to establish reference ranges for two consecutive CK measurements in individuals. For the outlier of individual CK differences (Fig. 1) , no obvious reason (such as age, body mass index, physical activity, medication) was found. Recent data indicate that inter-individual variability of CK activity in the general population is greater than previously suggested and that relatively high values frequently occur in different subgroups [6] . Those and our findings are consistent with the existing knowledge that males have higher values than females, as reflected by higher ULN than in females. However, higher CK activity levels per se are not sufficient to explain the higher intra-individual CK activity differences that we observed. Whatever the underlying reason may be, the existence of outstanding CK activity pairs will be important for subsequent studies evaluating CK alterations upon statin treatment initiation.
Our data do not allow conclusions about the clinical significance of CK alterations. Rather, our data will provide the basis for prospective studies to address the prognostic value of CK alterations and, specifically, minimum changes required to stop treatment. Legend: * ((CK2)/(CK1)) x 100%, i.e. percent of CK1. † determination of CI with the percentile method using bootstrap samplings (n=1000) [3] . Values of the target variables are bold. Physicians referring to recommendations to measure CK before and 10 weeks after initiation of statin treatment in patients at myopathy risk will benefit from such reference ranges. Furthermore, such reference ranges may be included in future statin trials using CK as a safety parameter.
CONCLUSION
It is concluded that CK serum activity substantially varies between two measurements. The present data provide the basis for developing reference ranges of CK activity pairs by simple variables.
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